Milestone Pharmaceuticals announced today that it has launched the RESET‑PSVT registry, a Phase 4 prospective observational study designed to collect real‑world evidence on its FDA‑approved nasal spray, CARDAMYST, for paroxysmal supraventricular tachycardia (PSVT).
The registry will enroll approximately 450 adult patients across about 20 electrophysiology and cardiology sites, with enrollment slated to begin by the end of 2026. It will be led by the Duke Clinical Research Institute and will capture patient‑ and provider‑reported outcomes, usage patterns, and healthcare utilization data. The study aims to deepen understanding of CARDAMYST’s real‑world effectiveness and quality‑of‑life impact, supporting future payer negotiations and market access strategies.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.